Albertsons (ACI) is likely to post a modest upside to identical sales growth estimate of 2% in Q4, RBC Capital Markets said in an earnings preview Thursday.
The consensus estimate was 1.7% for the quarter, the report said. Albertsons will release its Q4 results April 15.
Despite a stable top-line growth, the company faces risks to the fiscal year 2025 adjusted EBITDA positioning, RBC said.
"Pharmacy mix shift will remain a drag and we believe 1H investments are needed to unlock growth potential across retail media and owned brands," the report said.
RBC kept its outperform rating with a $23 price target.
Price: 22.89, Change: +0.46, Percent Change: +2.03
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。